IP Library › Assignment 074408/0977
Patent Assignment
Reel/Frame 074408/0977

Assignment of Assignor's Interest

Recorded: 2026-04-20 Pages: 7
Assignor
LUDWIG, DALE L.
Executed: 2026-02-25
Assignee
ACTINIUM PHARMACEUTICALS, INC.
100 PARK AVENUE, 23RD FLOOR, NEW YORK, NEW YORK, 10017
Covered Properties (39)
Radioconjugates Targeting CD33 in the Treatment of Cancers
Application: 63/230,431 →
Radioconjugates Targeting CD33 in the Treatment of Cancers
Application: 17/883,434 →
Publication: US 2023/0302167
Radioconjugates Targeting CD33 in the Treatment of Sarcomas
Application: 17/822,701 →
Publication: US 2023/0092668
Radioconjugates Targeting CD33 in the Treatment of Breast Cancer
Application: 19/384,310 →
Publication: US 2026/0053963
Radioimmunoconjugates Targeting Calreticulin for Use in the Treatment of Cancer
Application: 63/233,577 →
Radioimmunoconjugates Targeting Calreticulin for Use in the Treatment of Cancer
Application: 18/684,103 →
Publication: US 2024/0226345
Radioimmunoconjugates Targeting Phosphatidylserine for Use in the Treatment of Cancer
Application: 63/237,854 →
Radioimmunoconjugates Targeting Phosphatidylserine for Use in the Treatment of Cancer
Application: 18/685,667 →
Publication: US 2025/0339571
Trophoblast Glycoprotein Radioimmunotherapy for the Treatment of Solid Cancers
Application: 63/077,297 →
Trophoblast Glycoprotein Radioimmunotherapy for the Treatment of Solid Cancers
Application: 18/025,849 →
Publication: US 2023/0390424
Radioimmunoconjugates Targeting GRP78 for Use in the Treatment of Cancer
Application: 63/249,160 →
Radioimmunoconjugates Targeting GRP78 for Use in the Treatment of Cancer
Application: 18/696,453 →
Publication: US 2024/0390532
HER3 Radioimmunotherapy for the Treatment of Solid Cancers
Application: 63/116,225 →
HER3 Radioimmunotherapy for the Treatment of Solid Cancers
Application: 17/532,919 →
Publication: US 2022/0143228
HER3 Radioimmunotherapy for the Treatment of Solid Cancers
Application: 18/146,149 →
Publication: US 2023/0248855
HER3 Radioimmunotherapy for the Treatment of Solid Cancers
Application: 18/392,556 →
Publication: US 2025/0205375
Methods for Treating Cancer Using Combinations of Hdac Inhibitors and Antibody Radioconjugates
Application: 63/118,181 →
Methods for Treating Cancer Using Combinations of Epigenetic Therapies and Radioconjugate Targeting Agents
Application: 18/036,723 →
Publication: US 2025/0281654
Lewis Y Radioimmunotherapy for the Treatment of Cancer
Application: 63/122,026 →
Lewis Y Radioimmunotherapy for the Treatment of Cancer
Application: 17/544,522 →
Methods for Treating CD33-Positive Hematological Malignancies
Application: 63/298,532 →
Methods for Treating CD33-Positive Hematological Malignancies
Application: 18/728,076 →
Publication: US 2025/0073274
Radioconjugates Directed to Mhc-Complexed Antigens in Cancer
Application: 63/147,700 →
Radioconjugates Directed to Mhc-Complexed Antigens in Cancer
Application: 17/668,134 →
Radioimmunoconjugates Directed to CCR8 for Depletion of Tumor Infiltrating Regulatory T Cells
Application: 63/171,790 →
Radioimmunotherapy Directed to CCR8 for Depletion of Tumor Infiltrating Regulatory T Cells
Application: 18/553,757 →
Publication: US 2024/0197931
Radioimmunoconjugates Directed to NKG2D Ligands in Cancer
Application: 63/184,017 →
Radioimmunoconjugates Directed to NKG2D Ligands for the Treatment of Cancer
Application: 18/557,988 →
Publication: US 2024/0216554
Radioconjugates Targeting CD33 in the Treatment of Cancers
Radioimmunoconjugates Targeting Calreticulin for Use in the Treatment of Cancer
Radioimmunoconjugates Targeting Phosphatidylserine for Use in the Treatment of Cancer
Trophoblast Glycoprotein Radioimmunotherapy for the Treatment of Solid Cancers
Radioconjugates Targeting GRP78 for Use in the Treatment of Cancer
HER3 Radioimmunotherapy for the Treatment of Solid Cancers
HER3 Radioimmunotherapy for the Treatment of Solid Cancers
Methods for Treating Cancer Using Combinations of Epigenetic Therapies and Radioconjugate Targeting Agents
Methods for Treating CD33-Positive Hematological Malignancies
Radioimmunotherapy Directed to CCR8 for Depletion of Tumor Infiltrating Regulatory T Cells
Radioimmunoconjugates Directed to NKG2D Ligands for the Treatment of Cancer
Related Assignments (12)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Sep 11, 2020
From: LUDWIG, DALE; GEOGHEGAN, EILEEN
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 053750/0138 →
Assignment of Assignor's Interest Nov 20, 2020
From: LUDWIG, DALE L; GEOGHEGAN, EILEEN
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 054427/0633 →
Assignment of Assignor's Interest Dec 6, 2020
From: LUDWIG, DALE
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 054556/0948 →
Assignment of Assignor's Interest Dec 7, 2020
From: LUDWIG, DALE L; GEOGHEGAN, EILEEN M
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 054560/0604 →
Assignment of Assignor's Interest Feb 9, 2021
From: LUDWIG, DALE L
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 055204/0936 →
Assignment of Assignor's Interest Apr 7, 2021
From: GEOGHEGAN, EILEEN; LUDWIG, DALE L; SETH, SANDESH; HWANG, JESSE
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 055854/0296 →
Assignment of Assignor's Interest May 4, 2021
From: GEOGHEGAN, EILEEN; LUDWIG, DALE L; HWANG, JESSE
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 056133/0600 →
Assignment of Assignor's Interest Mar 13, 2023
From: LUDWIG, DALE; GEOGHEGAN, EILEEN
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 062967/0143 →
Assignment of Assignor's Interest Mar 13, 2023
From: LUDWIG, DALE; GEOGHEGAN, EILEEN
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 062967/0167 →
Assignment of Assignor's Interest Apr 19, 2026
From: SETH, SANDESH
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 074408/0883 →
Assignment of Assignor's Interest Jul 28, 2026
From: DIAMOND, PAUL
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 075413/0388 →
Assignment of Assignor's Interest Jul 28, 2026
From: GEOGHEGAN, EILEEN
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 075413/0363 →